Bucharest

• RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHAR … Ended
  2023-510247-38-00 3 2024-06-07 Rheumatoid arthritis
• Clinical trial of V940 and pembrolizumab in people with resectable locally advanced cutaneous squamous cell carcinoma Ended
  2023-505712-37-00 10 2024-06-06 The participants must have a histologically confirmed diagnosis of res
• Multiple Ascending Doses of BMS-986326 in Participants with Discoid Lupus Erythematosus, Subacute Cutaneous Lupus Erythematosus, or Systemic … Ended
  2022-503009-39-00 3 2024-06-04 Subacute Cutaneous Lupus Erythematosus
• A Pharmacokinetics (PK) study to compare GME751 (proposed pembrolizumab biosimilar) and United States (US)-licensed and European Union (EU)- … Ended
  2023-506881-30-00 3 2024-05-15 Melanoma
• A study to investigate the safety, tolerability, and pharmacokinetics of Ent001 in patients with moderately to severely active ulcerative co … Ended
  2023-507340-36-00 3 2024-04-22 Inflammatory bowel disease (moderate to severe active ulcerative colit
• MLS-101-301: A Randomized, Double-Blind, Placebo Controlled, Parallel Arm, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of … Ended
  2023-506425-12-00 5 2024-04-17 Uncontrolled and Resistant Hypertension
• Regorafenib-pembrolizumab vs. TACE/TARE in intermediate-stage HCC beyond up-to-7. Ended
  2022-501969-42-00 5 2024-03-28 Intermediate-stage hepatocellular carcinoma with beyond up-to-7 criter
• A Phase 3 study to assess efficacy and safety of oral tebipenem compared to IV imipenem-cilastatin in adults with cUTI/AP Ended
  2023-503785-22-00 5 2024-03-25 complicated urinary tract infection (cUTI) or acute pyelonephritis (AP
• Study on immunogenicity and safety of a meningococcal ACYW conjugate vaccine in healthy infants and toddlers Ended
  2023-508177-85-00 5 2024-03-12 Healthy volunteers (Meningococcal infection)
• A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or With … Ended
  2023-507280-18-00 5 2024-02-23 Type 2 Diabetes
• A 12-week double-blind, multicentre, randomised, active-controlled, 2-arm, parallel-group clinical trial to evaluate the safety of CHF5993 p … Ended
  2023-503333-22-00 5 2024-01-15 Moderate to severe controlled asthma according to Step 4 and Step 5 of
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Inhalation of Seralutinib for the … Ended
  2023-503614-80-00 5 2023-12-14 Pulmonary Arterial Hypertension
• Efficacy and Safety of JNJ-77242113 in Participants with Moderately to Severely Active Ulcerative Colitis Ended
  2023-504673-20-00 4 2023-12-06 Ulcerative Colitis
• A PHASE 2 STUDY EVALUATING INCB099280 IN PARTICIPANTS WITH SELECT SOLID TUMORS WHO ARE IMMUNE CHECKPOINT INHIBITOR–NAÏVE Ended
  2022-502716-37-00 4 2023-11-27 Recurrent or advanced/metastatic solid tumors who are immunotherapy na
• Efficacy and safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund maintenance therapy Ended
  2022-502208-64-00 4 2023-11-25 Asthma
• A large global trial to evaluate the efficacy and safety of milvexian in reducing recurrent cardiovascular events in patients after a heart … Ended
  2022-501418-69-00 5 2023-11-21 Acute Coronary Syndrome
• A study in people with moderately to severely active ulcerative colitis to see how well an investigational treatment called PB016 works and … Ended
  2022-502778-18-00 5 2023-11-17 ulcerative colitis
• A clinical study of MK-8527 in people with HIV-1 (MK-8527-004) Ended
  2023-503682-39-00 3 2023-11-13 HIV-1 (Human Immunodeficiency Virus Type 1)
• REIMAGINE 2: A research study to see how well CagriSema compared to semaglutide, cagrilintide and placebo lowers blood sugar and body weight … Ended
  2022-502678-18-00 5 2023-11-07 Type 2 diabetes
• A trial to evaluate the efficacy and safety of different doses of LEO 138559 in adults with moderate-to-severe atopic dermatitis. Ended
  2022-500777-14-00 4 2023-11-06 Atopic Dermatitis
• A Phase 2 Study Evaluating INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma Ended
  2022-502476-23-00 4 2023-10-25 Treatment of immunotherapy-naive patients with previously untreated or
• A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adult … Ended
  2022-502552-31-00 4 2023-10-03 Relapsing Forms of Multiple Sclerosis
• A Multi-national Phase IIIb Trial to Determine the Safety and Efficacy of STALORAL® Birch 300 IR in Children and Adolescents 5 to 17 Years o … Ended
  2023-509833-38-00 5 2023-09-20 Birch Pollen-induced Allergic Rhinoconjunctivitis
• A Study of LY3437943 in Participants with Type 2 Diabetes Mellitus who have Obesity or Overweight (TRIUMPH-2) Ended
  2023-503658-11-00 5 2023-08-31 Type 2 Diabetes

Showing 529–552 of 653 trials